Progranulin and CTRP3 in Metabolic Syndrome

Completed

• Conditions: Metabolic Syndrome

• Registration Number: NCT01668888
• Lead Sponsor: Korea University

Brief Summary

Inflammation has been known to be a pivotal pathogenic mechanism of obesity-related disorders such as type 2 diabetes, metabolic syndrome and atherosclerosis. Adipose tissue functions as a major endocrine organ by adipokine mediated modulation of a number of signaling cascades in target tissues, that has pro-inflammatory or anti-inflammatory activities. Progranulin and CTRP3 are recently discovered novel adipokines. Therefore, the investigators tried to clarify the clinical meaning of these two adipokines in the subjects with or without metabolic syndrome

Detailed Description

Not available

Study Timeline

• Study Start: 2012-05
• Status Verified: 2012-08
• Primary Completion: 2012-08
• Study Completion: 2012-08
• Study First Submitted: 2012-08-14
• Study First Submitted QC: 2012-08-16
• Last Update Submitted: 2012-08-16
• Study First Posted: 2012-08-20
• Last Update Posted: 2012-08-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 127

Inclusion Criteria

• 20<age<80
• apparently healthy subjects

Exclusion Criteria

• a history of CVD
• diabetes
• stage 2 hypertension
• malignancy
• severe renal or hepatic disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum concentration of progranulin in the subjects with metabolic syndrome	12week
Serum concentration of CTRP3 in the subjects with metabolic syndrome	12week

Secondary Outcome Measures

Name	Time	Method
The relationship of serum progranulin levels with cardiovascular risk factors	12 week
The relationship of serum CTRP3 levels with cardiovascular risk factors	12 week

Trial Locations

Locations (1)

Korea University Guro Hospital; 🇰🇷 Seoul, Korea, Republic of